The IL-13 inhibitor improved several life quality measures in adult patients.

Tralokinumab, an interleukin-13 (IL-13) inhibitor approved for the treatment of moderate-to-severe atopic dermatitis (AD) in adults, was shown to improve several quality of life measures, a 6-month interim analysis suggests.

The drug has been shown previously to improve patient-reported outcomes in clinical trials and also after a month of use in real-world settings. For the interim analysis of the ongoing year-long patient survey study enrolled AD patients from the Adbury™ Advocate™ Program. Prior to drug initiation, patients filled out surveys at baseline. The surveys included weekly itch numeric rating scale (NRS), eczema-related weekly sleep NRS, the Dermatology Quality of Life Index (DLQI), and the Treatment Satisfaction Questionnaire for Medication (TSQM-9). The researchers measured percent change from baseline to 6 months, and outcomes were stratified by use of dupilumab use. They also included the percentage of patients experiencing minimal clinically important difference (MCID) for itch NRS and DLQI.

According to the results, 102 patients completed the surveys at baseline, one month, and six months (59.8% female; mean age, 44.2 years; 84.3% previously treated with topical corticosteroids and 52.9% had experience with dupliumab). The authors noted improvement in mean sleep interference NRS (40%), average weekly itch NRS (39%), worst weekly itch NRS (33%), PO-SCORAD (37%), and DLQI (52%). The team also reported improvements in mean TSQM-9 global satisfaction (11.06 points), TSQM-9 convenience (3.92 points), and TSQM-9 effectiveness (14.60 points). Notably, dupilumab-naïve patients showed significantly improved outcomes when compared to those with dupilumab experience). The researchers plan to continue follow-up to 52 weeks of treatment.

“Within the dupilumab-experienced cohort, there were differences in treatment response, with many patients experiencing meaningful improvements across endpoints, while others did not see improvement,” the authors wrote in their poster. “In a real-world setting, tralokinumab presents as an effective option for patients to manage their AD, regardless of their previous experience with dupilumab.”

Source: Lio P, Kim Y, Balu S, et al. Tralokinumab Real-World Patient-Reported Outcomes in Moderate-to-Severe Atopic Dermatitis Adult Patients in the United States: 6-Month Interim Analysis. Abstract 12526. Presented at: Maui Derm, January 22-26, 2024.

Disclosures

This study was funded by LEO Pharma USA.